Cancer Cell Equipment
-
Manufactured by The Electrospinning Company Ltd.based in UNITED KINGDOM
Images taken using a Nikon Eclispe C1 confocal microscope. HepG2 liver cells were grown for 21 days in the Mimetix scaffold. Cells are stained with DAPI and actin; fibres are electrospun together with Rhodamine 6G (a and b). Cancer cells form a 3D network inside the scaffold (c), use the fibres to support themselves (d) and ...
-
Manufactured by The Electrospinning Company Ltd.based in UNITED KINGDOM
The Mimetix fibres are labelled with Rhodamine 6G. The thickness of Mimetix scaffold allows for having a 3D environment while maintaining a certain translucence, thus allowing for easy and robust imaging. This study has investigated the localisation depth of MCF7 breast cancer cells in the Mimetix scaffold after 4 days of culture (nuclei ...
-
Manufactured by Gritstone Biobased in USA
We are leveraging EDGE to define targets for T-cell receptor (TCR) directed cell therapies. These additional targets that were identified and validated by Gritstone EDGE™ enable us to partner with others or develop additional therapeutic approaches to redirect T cells onto tumors using these highly specific ...
-
Manufactured by BriaCell Therapeutics Corp.based in CANADA
The mechanism of action of Bria-IMT™/Bria-OTS™ is currently under investigation. We believe that Bria-IMT™/Bria-OTS™, activates the patient’s immune system to recognize tumor cells and destroy them. We hypothesize that Bria-IMT™/Bria-OTS™, exert their action by stimulating the antigen-presentation ...
-
Manufactured by Filtricine, Inc.based in USA
The hyperactive metabolism of cancer cells is extensively modified to support their unsustainable consumption of nutrients, which is what allows cancer cells to reproduce rapidly. Yet cancer cells lose their ability to make certain nutrients on their own like healthy cells do. ...
-
Manufactured by Mol Scientificbased in CHINA
Mol Scientific offer high-quality Cancer cell proliferation inhibitor peptide product(MPE0003430). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive prices. ...
-
Manufactured by OncoVITAbased in FRANCE
Oncovita’s MeasovirTM proprietary platform relies on a DNA plasmid vector that expresses a modified measles Schwarz virus antigenome able to generate recombinant viruses by using a clonal reverse genetics system. This versatile plug-and-play platform allows producing new viruses expressing very large amounts of additional genetic ...
-
Manufactured by Filtricine, Inc.based in USA
Filtricine’s Innovative Technology Restricts Nutritional Support to Cancer Cells. Our strategy is to eliminate cancer cells’ access to non-essential amino acids, which the cancer cells require for growth. Our first technology is used in the development of exclusive replacement meals ...
-
Manufactured by BriaCell Therapeutics Corp.based in CANADA
-IMT™ is a genetically engineered human breast cancer cell line with features of immune cells. It is clinically used as a targeted ...
-
Manufactured by Jubilant Therapeutics Inc.based in USA
Strong scientific and clinical rationale for LSD1/HDAC6 inhibition in haematological and solid ...
-
Manufactured by Senti Biosciencesbased in USA
Pursuing an Unmet Need in the Treatment of CRC - SENTI-401 is designed to more precisely target and eliminate colorectal cancer (CRC) cells while sparing healthy cells elsewhere in the body. Our vision is a potential medicine that more effectively treats patients with colorectal ...
-
Manufactured by Creative Bioarraybased in USA
Human (Parental) Brain Cancer Stem Cell (Plated cells are also available). 120 Population doublings or up to 12 passages. One million viable cells upon thawing of frozen cells, frozen vial of cells shipped in dry-ice. Cell Cultures from single donors, 1000 different ...
-
Manufactured by Kiadis Pharma NVbased in NETHERLANDS
K-NK00X: Kiadis is evaluating preclinical programs with K-NK-cell therapies for the treatment of hematologic and solid ...
-
Manufactured by Kiadis Pharma NVbased in NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be ...
-
Manufactured by Kiadis Pharma NVbased in NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
-
Manufactured by IMV Inc.based in CANADA
Maveropepimut-S (DPX-Survivac) combines the advantages of the DPX platform and the cancer antigen survivin, is the lead candidate of IMV’s new class of immunotherapies that generates cancer-targeted T cells in ...
-
Manufactured by Eutilex Co.,Ltd.based in SOUTH KOREA
4th generation GPC3 CAR-T shows better efficacy compared to 2nd generation GPC3 CAR-T; Shows better efficacy for tumor clearance than 2nd generation GPC3 CAR-T in vivo; Clear anti-cancer efficacy in an orthotopic model; Smaller number of 4th generation GPC3 CAR-T required than other groups to remove ...
-
Manufactured by Lineage Cell Therapeutics, Inc.based in USA
VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells. VAC2, which is produced from our pluripotent cell technology using a directed differentiation ...
-
Manufactured by Vitro Biopharmabased in USA
High passage capabilities. Expands in VitroPlusIII Low Serum, Complete Medium (Vitro Biopharma, Cat. No. PC00B1–optimized for high growth rates, reduced doubling times, healthy cells, and stability). Able to grow in low oxygen (1% - 5% O2). Available for research ...
-
Manufactured by Ocean Biomedicalbased in USA
New therapeutic antibodies for effective treatment of NSCLC and other disorders. We are moving towards Phase 1 clinical trials of patented antibodies for the treatment of NSCLC. Our lead program, OCX-253 was chosen because it stimulates the B-Raf protooncogene while inhibiting apoptosis, NK cell accumulation and activation, LIM kinase 2, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you